Microbot Medical Inc.
MBOTNASDAQHealthcareMedical - Devices
Regular session
$1.495
−$0.005 · -0.33%
MBOT company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
29
Weakening
Sentiment
64
Bullish
Risk resilience
31
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteMicrobot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Harel Gadot
- Listed since
- Mar 25, 1992
- Employees
- 43
Market position
Day range
Current $1.495
52-week range
Current $1.495
- Open
- $1.47
- Previous close
- $1.50
- Volume
- 684.52K
- 0.58× average
- Average volume
- 1.17M
- Average daily volume
- Market cap
- 68.13M USD
- Beta
- 1.05
- Market reference 1
- 50-day average
- $1.7768
- -15.86% below average
- 200-day average
- $2.0678
- -27.70% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 88.53M USD
- P/E (TTM)
- -5.73×
- P/B (TTM)
- 1.46×
- P/S (TTM)
- 196.9×
- EV / EBITDA
- -6.76×
- Earnings yield
- -14.35%
- Free cash flow yield
- -14.31%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -185.26%
- Operating margin
- -5348.84%
- Net margin
- -4722.25%
- Return on equity
- -16.95%
- Return on assets
- -16.12%
- Return on invested capital
- -18.80%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 23.33×
- Altman Z-score
- 7.46
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 91K USD | 106K USD | — | — |
| Gross profit | — | −91K USD | −106K USD | — | — |
| Research and development | 6.28M USD | 6.63M USD | 5.72M USD | 7.74M USD | 6.15M USD |
| Selling, general, and administrative | 8.25M USD | 5M USD | 4.13M USD | 5.58M USD | 5.41M USD |
| Operating expenses | 14.74M USD | 11.53M USD | 9.75M USD | 13.28M USD | 11.36M USD |
| Interest income | 1.29M USD | 182K USD | 228K USD | 54K USD | 44K USD |
| Depreciation and amortization | 47K USD | 91K USD | 106K USD | 102K USD | 76K USD |
| Operating income | −14.74M USD | −11.63M USD | −9.86M USD | −13.28M USD | −11.36M USD |
| Net income | −13.14M USD | −11.44M USD | −10.74M USD | −13.17M USD | −11.31M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 27%
- 3 beats, 6 misses, 2 met estimates
- Average EPS surprise
- +2.78%
- 11 comparable reports
- Latest EPS result
- -0.08
- Estimate -0.08 · Miss by 4.34%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$4.00
167.56% upsideRating distribution
4 ratingsLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Recent analyst actions
MBOT news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 5, 2018 | 1:15 | — | — |
Stock split | Nov 29, 2016 | 1:9 | — | — |
Stock split | May 9, 2016 | 1:12 | — | — |
Stock split | Jul 6, 2011 | 1:10 | — | — |
Effective Sep 5, 2018
1:15
Effective Nov 29, 2016
1:9
Effective May 9, 2016
1:12
Effective Jul 6, 2011
1:10
MBOT peers
ETFs holding MBOT
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI3.63M0.00%2.3T USD0.03%$377.51-0.19%
Vanguard Extended Market ETFVXF1.29M0.00%93.7B USD0.05%$243.72-0.74%
iShares Micro-Cap ETFIWC350.94K0.02%1.53B USD0.60%$196.56-0.80%
Avantis U.S. Small Cap Equity ETFAVSC139.04K—3.16B USD0.25%$73.505-0.45%
Invesco NASDAQ Future Gen 200 ETFQQQS82.63K0.36%22.98M USD0.20%$44.52-1.25%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 3.63M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $377.51-0.19%
Vanguard Extended Market ETFVXF- Market value
- 1.29M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $243.72-0.74%
iShares Micro-Cap ETFIWC- Market value
- 350.94K
- Weight
- 0.02%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $196.56-0.80%
Avantis U.S. Small Cap Equity ETFAVSC- Market value
- 139.04K
- Weight
- —
- AUM
- 3.16B USD
- Expense ratio
- 0.25%
- Price / 1D
- $73.505-0.45%
Invesco NASDAQ Future Gen 200 ETFQQQS- Market value
- 82.63K
- Weight
- 0.36%
- AUM
- 22.98M USD
- Expense ratio
- 0.20%
- Price / 1D
- $44.52-1.25%
Continue in GoAI
Research MBOTresearch.disclaimer